Alpha 2.0
Login Register
» Authors » Joan A Arnaiz

Joan A Arnaiz

Explore the profile of Joan A Arnaiz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 81
Followers 0
Related Specialties
Infectious Diseases
Microbiology
General Medicine
Top 10 Co-Authors
Josep Mallolas
Jose M Gatell
Judit Pich
Montserrat Laguno
Esteban Martinez
Jose L Blanco
Agathe Leon
Elisa de Lazzari
Daniel Podzamczer
Jhon Rojas
Published In
Antivir Ther
J Antimicrob Chemother
Pharmacogenet Genomics
J Acquir Immune Defic Syndr
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers
Barroso S, Moren C, Gonzalez-Segura A, Riba N, Arnaiz J, Manriquez M, et al.
PLoS One . 2019 May; 14(5):e0216712. PMID: 31120908
Context: Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and integrase inhibitors are supposed to be safer, but have...
2.
Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: impact of the serotonin pathway
Mas S, Blazquez A, Rodriguez N, Boloc D, Lafuente A, Arnaiz J, et al.
Pharmacogenet Genomics . 2016 Sep; 26(11):487-496. PMID: 27660918
Objective: Pharmacogenetic studies of fluoxetine in children and adolescents are scarce. After reporting the effect of genetic variants in genes related to the fluoxetine pharmacokinetics on clinical response in a...
3.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Leal L, Leon A, Torres B, Inciarte A, Lucero C, Mallolas J, et al.
J Antimicrob Chemother . 2016 Mar; 71(7):1982-6. PMID: 26994091
Objectives: The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc, both with tenofovir disoproxil/emtricitabine as the backbone. Methods: We...
4.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection
Leal L, Leon A, Torres B, Inciarte A, Lucero C, Mallolas J, et al.
J Antimicrob Chemother . 2016 Mar; 71(7):1987-93. PMID: 26994089
Objectives: The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing two regimens. Methods: A prospective, open, randomized clinical trial was conducted at a...
5.
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
Martinez E, Arranz J, Podzamczer D, Lonca M, Sanz J, Barragan P, et al.
J Acquir Immune Defic Syndr . 2009 Apr; 51(3):290-7. PMID: 19398921
Background: Data comparing abacavir/lamivudine versus tenofovir/emtricitabine in antiretroviral-naive patients are controversial. We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression. Methods:...
6.
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients
Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, Vidal S, et al.
Antivir Ther . 2007 Jun; 12(3):407-15. PMID: 17591031
Background: Stavudine (d4T)-containing regimens are associated with a potential for lipoatrophy and dyslipidaemia. We assessed the safety and efficacy of reducing the dose of stavudine compared with switching to tenofovir...
7.
Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy
Badia X, Podzamczer D, Moral I, Roset M, Arnaiz J, Lonca M, et al.
Antivir Ther . 2005 Jan; 9(6):979-85. PMID: 15651756
Objective: To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. Methods:...